DOCKETANO UP-0307

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Evan C. Unger, et al.

Serial No.: 09/218,660

Group Art Unit: 1619

Filing Date: December 22, 1998

Examiner: S. Sharareh

NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND

THERAPEUTIC USE

HEREBY CERTIFY THAT

THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO

OMMISSIONER FOR PATENTS,

TYPED NAME: REGISTRATION NO.: 43,966

Assistant Commissioner for Patents Washington DC 20231

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first office action after the filing of request for continued examination under §1.114, no additional fee is required.

	In accordance with §1.129(a), this Information Disclosure Statement is being
	filed in connection with \square the first or \square second After Final Submission,
	therefore:
	☐ Certification in Accordance with §1.97(e) is attached; or
	The fee of $$180.00$ as set forth in $$1.17(p)$ is attached.
\boxtimes	In accordance with §1.97(c), this Information Disclosure Statement is being filed
	after the period set forth in §1.97(b) above but before the mailing date of either
	a Final Action under §1.113 or a Notice of Allowance under §1.311, or before an
	action that otherwise closes prosecution in the application, therefore:
	☐ Certification in Accordance with §1.97(e) is attached; or
	The fee of \$180.00 as set forth in \$1.17(p) is attached.
	In accordance with §1.97(d), this Information Disclosure Statement is being filed
	after the mailing date of either a Final Action under §1.113 or a Notice of
	Allowance under §1.311 but before, or simultaneously with, the payment of the
	Issue Fee, therefore included are: Certification in Accordance with §1.97(e); and
	the submission fee of \$180.00 as set forth in \$1.17(p).
\boxtimes	Copies of each of the references listed on the attached Form PTO-1449 are
	enclosed herewith.
	Copies of references listed on the attached Form PTO-1449 are enclosed herewith
	EXCEPT THAT:
	In view of the voluminous nature of references [list as appropriate], and
	the likelihood that these references are available to the Examiner, copies

In accordance with §1.98(d), copies of the following references listed on
the attached Form PTO-1449 are not enclosed herewith because they were
previously cited by or submitted to the U.S. Patent and Trademark Office
in patent application(s) for which a claim for priority under 35
U.S.C.§120 have been made in the instant application:

Copies of references [list as appropriate] listed on the attached Form

PTO-1449 were previously cited by or submitted to the Patent and

Trademark Office in prior application Serial No. , filed .

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

There are no listed references which are not in the English language.

Date:

S. Maurice Valla

Registration No. 43,966

WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP One Liberty Place - 46th Floor Philadelphia, PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2000 WWKMN